PrEP Biopharm

About PrEP Biopharm Limited


Ryan Muldoon

Ryan Muldoon Co-Founder and Chief Executive Officer

Ryan co-founded PrEP Biopharm after spending 15 years as a commercial executive at Janssen, Forest Laboratories, and Bristol-Myers Squibb. Most recently Ryan was responsible for New Business Development within the Infectious Diseases & Vaccines group at Janssen, helping to secure several licenses and acquisitions for the group. While at Janssen, he also was the Global Commercial Leader for Hepatitis.

Prior to Janssen, Ryan spent time at Bristol-Myers Squibb as the global commercial leader for viral hepatitis, the Country Manager of Sweden, and the US launch leader for HIV compounds.

Ryan has a Masters of International Management from Thunderbird School of Global Management and a BA in German Literature and English from Emory University

Bruce A. Malcolm, PhD

Co-Founder and Chief Scientific Officer

Bruce co-founded PrEP Biopharm after spending 25 years in industry and academia focused on infectious diseases. Most recently, Bruce was the co-inventor and early development team leader of PrEP-001 at Janssen. Prior to that, as Senior Director of Discovery and Early Development, he led Janssen discovery efforts on HIV therapies and “cures.” Bruce led the discovery team and was a co-inventor of VictrelisTM which was the first direct antiviral agent against HCV launched by Schering-Plough/Merck in 2012. Prior to that, he was a professor of biochemistry at the University of Alberta, and began his career in drug discovery at Chiron Corporation in Emeryville, California.

Bruce received his PhD in biochemistry and molecular and cellular biology from University of California, Berkeley.

Anna Slater

Head of Chemistry, Manufacturing & Controls

Anna Slater has 30 years of industry experience in pharmaceutical development, scale-up, manufacturing, regulatory filing and launch across a broad range of dosage forms, delivery devices and therapeutic areas. She spent 28 years at GlaxoSmithKline in a wide range of CMC capacities. Most recently she was the Global Head of Analytical Technologies and CMC lead for ARNUITY™ ELLIPTA™ and VI Monotherapy. Prior to that she was a Senior Director in the global Inhaled Product & Device Technology Leadership Team, with accountability for CMC development of drug products and delivery devices for the GSK intranasal and allergy portfolio (Candidate Selection to Launch) and managing a department responsible for aqueous respiratory products and the RELENZA™ ROTACAP™ Pandemic Response.

Anna received her BSc in Chemistry from University College London

Ron Turner, MD

Chief Medical Officer

Dr. Turner is also a Professor of Pediatric Infectious Diseases at the University of Virginia Medical School and is a globally recognized Key Opinion Leader in the field of respiratory viral infections.

He has served as the Associate Dean for Clinical Research at UVA, the Head of the Division of Pediatric Infectious Diseases at the Medical Univ. of South Carolina, served as a reviewer of multiple scientific journals including JAMA, New England Journal of Medicine and Clinical Infectious Diseases. He has published over 140 articles, reviews and book chapters and served as a consultant to many companies researching respiratory viral infections.

He received his BS in Chemistry from Southern Illinois University and MD from the Southern Illinois University Medical School.